Active Biotech’s partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer

Lund, April 12, 2018 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumomab Estafenatox) at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago on April 14-18, 2018. The poster Naptumomab Estafenatox Induces T cells Tumor Recognition, Turning anti-PD1 Unresponsive “Cold” Tumors into “Hot” Responsive Tumors will be presented between 1:00 p.m. and 5:00 p.m. local time on April 16, 2018, at the session “Immune Checkpoints 2”. The data to be presented demonstrates a synergistic anti-tumor effect when ANYARA is combined with a PD-1 checkpoint inhibitor in several different tumor models that are marginally responsive to
PD-1 inhibition.

Read the press release here.